Lilly’s oral GLP-1 drug Orforglipron outperforms Semaglutide in phase 3 diabetes trial

Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter

Novo Nordisk's Zenagamtide shows strong HbA1c and weight loss benefits in phase II trial

Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions

Dr. Reddy’s and Nestle Health Science launch Celevida GLP for optimized nutritional support

Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass

MSN Laboratories launches SEMABEST, India-made semaglutide pen at nearly 50% lower price

CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing

India’s Diabetes Crisis: Awareness and monitoring gaps threaten millions

According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic

Sourav Ganguly launches Beurer India's GL 22 Blood Glucose Monitor

The GL 22 Blood Glucose Monitor combines German precision with advanced technology designed to meet local needs

Roche’s Vabysmo improved vision in underrepresented populations with DME in a first-of-its-kind study

Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies

Sucralose safe to use in small doses; reveals MDRF study

Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers

Akums gets approval for triple combination diabetes treatment

BeatO appoints Dr. Navneet Agrawal as Chief Clinical Officer

He has published more than 100 research papers in several prestigious national and international journals